Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 9,143 matching trials from the live ClinicalTrials.gov search.

Filters: Rochester, Minnesota Clear all

Conditions: IgA Nephropathy
Interventions: OMS721, Vehicle (D5W or saline); Biological · Other
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 34
States / cities: Florence, Alabama • Mesa, Arizona • Phoenix, Arizona + 29 more

Conditions: Irritable Bowel Syndrome
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 16
States / cities: Huntsville, Alabama • North Little Rock, Arkansas • Chula Vista, California + 13 more

Conditions: Stroke
Interventions: Occupational therapy- Repetitive Facilitative Exercise; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: American ginseng, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 326
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 208 more

Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Laboratory Biomarker Analysis, Paclitaxel, Pelareorep; Other · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 36
States / cities: Burbank, California • Mountain View, California • Hartford, Connecticut + 30 more

Conditions: Sleep Apnea, Obstructive
Interventions: Coblation (radiofrequency-based device); Device
Lead sponsor: ArthroCare Corporation; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sepsis, Low Blood Pressure
Interventions: Midodrine, Standard of Care; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 5
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Mankato, Minnesota + 2 more

Conditions: Cancer
Interventions: Ovarian tissue cryopreservation; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: Up to 17 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2040
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diffuse Large B Cell Lymphoma
Interventions: Not listed
Lead sponsor: MorphoSys AG; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: Rochester, Minnesota • St Louis, Missouri • Manhasset, New York + 5 more

Conditions: Melanoma
Interventions: Nivolumab + Relatlimab, rHuPH20; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Enrollment: 579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 15
States / cities: Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 12 more

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Venetoclax; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 176
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 143 more

Conditions: Dry Eye Disease
Interventions: Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane, Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 32
States / cities: Phoenix, Arizona • Glendale, California • Long Beach, California + 27 more

Conditions: Irritable Bowel Syndrome
Interventions: Rimegepant 75 MG [Nurtec]; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Familial Amyloid Polyneuropathy, Familial Amyloidosis
Interventions: diflunisal, placebo; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 3
States / cities: Boston, Massachusetts • Rochester, Minnesota • New York, New York

Conditions: Superficial Bladder Cancer
Interventions: Not listed
Lead sponsor: University of Sydney; Other
Eligibility: 18 Years and older
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Kansas City, Kansas • Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Arthritis, Osteoarthritis
Interventions: tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo; Biological · Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 832 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 94
States / cities: Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 72 more

Conditions: Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma, Colon Adenocarcinoma
Interventions: Guardant Reveal; Diagnostic Test
Lead sponsor: Guardant Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 33
States / cities: Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 30 more

Conditions: Lyme Disease
Interventions: mRNA-1975, mRNA-1982, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 807 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 20
States / cities: Milford, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 17 more

Conditions: Blood Coagulation, Disorders, Surgical Procedures, Minimally Invasive
Interventions: Fresh Frozen Plasma Transfusion; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 1 Year and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 2 Diabetes
Interventions: Colesevelam hydrochloride; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 46
States / cities: Jonesboro, Arkansas • Beverly Hills, California • Carmichael, California + 43 more

Conditions: Osteoid Osteoma
Interventions: MRgFUS, CTgRFA; Device
Lead sponsor: Matthew Bucknor; Other
Eligibility: 8 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 3
States / cities: Palo Alto, California • San Francisco, California • Rochester, Minnesota

Conditions: Heavy Dose Drinkers
Interventions: Magnetic Resonance Spectroscopy; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cancer, Multiple Indications
Interventions: Anti-PDL-1 antibody; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 11
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 7 more

Conditions: Cardiopulmonary
Interventions: Not listed
Lead sponsor: Prolaio; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Scottsdale, Arizona • Palo Alto, California • San Francisco, California + 11 more

Search by objective public record fields.

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome

Use of Repetitive Facilitative Exercise Program in Established Stroke

American Ginseng in Treating Patients With Fatigue Caused by Cancer

Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Study to Evaluate Recovery From Postoperative Pain After Sleep Apnea Surgery

MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial

Ovarian Tissue Cryopreservation in Children

Lenalidomide Monotherapy in R/R DLBCL

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

Comparison of Rimegepant and Placebo for Pain in IBS

The Effect of Diflunisal on Familial Amyloidosis

Evaluation of a Patient-Reported Symptom Index for NMIBC

Tanezumab In Osteoarthritis Of The Knee (2)

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age

Is Plasma Transfusion Beneficial Prior to Low-Risk Procedures in Hospitalized Patients With Blood Clotting Abnormalities?

WelChol® With Metformin in Treating Patients With Type 2 Diabetes

Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas

MRS Probe Study of Alcohol

Multiple Ascending Dose (MDX1105-01)

Observational, Non-Interventional Study Supporting Validation of eVO2peak Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests (CPET)